Publication | Open Access
A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma
64
Citations
24
References
2016
Year
Neuro-oncologyLow Dose BevacizumabMedicineStandard Dose BevacizumabMetronomic TherapyClinical TrialsPharmacotherapyNeurologyHigh-grade GliomasCancer TreatmentRecurrent GlioblastomaOncologyGliomaGlioblastoma
| Year | Citations | |
|---|---|---|
Page 1
Page 1